Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000058.xml
Planta Med 2024; 90(07/08): 561-575
DOI: 10.1055/a-2255-7096
DOI: 10.1055/a-2255-7096
Biological and Pharmacological Activity
Original Papers
Withanolide Profile and Acetylcholinesterase Inhibitory Activity of Two Argentinean Jaborosa Species[ # ]
This work was supported by the Austrian Agency for Education and Internationalization (OeAD) and the Argentinean Ministry of Science and Technology (WTZ, Grant AR09/2015).
Abstract
Acetylcholinesterase (AChE) inhibitors are still an important option for managing symptoms of mild to moderate Alzheimerʼs disease. In this study, we aimed to evaluate the potential in vitro AChE inhibitory activity of two Argentinian endemic Solanaceae species, Jaborosa bergii and J. runcinata. UHPLC-DAD-HRMS metabolite profiling revealed the presence of withanolides in the active CH2Cl2 subextracts. Their fractionation led to the isolation and identification of two known spiranoid withanolides from J. runcinata and three new withanolides with a skeleton similar to that of trechonolide-type withanolides from J. bergii. The known compounds showed moderate AChE inhibitory activity, while the new ones were inactive.
Keywords
Withanolides - Jaborosa bergii - Jaborosa runcinata - Solanaceae - Alzheimerʼs disease - cholinesterase inhibition# This work is dedicated to Professors Rudolf Bauer, Chlodwig Franz, Brigitte Kopp, and Hermann Stuppner for their invaluable contributions and commitment to Austrian Pharmacognosy.
Supporting Information
- Supporting Information
In the supporting information, the experimental NMR spectra of compound 1 and compounds 2/3, the experimental HRMS spectra of compounds 1–3, the annotations of the peaks detected in the UHPLC-DAD-HRMS chromatograms of the CH2Cl2 extracts JRD and JBD, and the IC50 curves of the ethanol extracts JRE and JBE, the CH2Cl2 extracts JRD and JBD, and the isolated compounds 4 and 5 are available.
Publication History
Received: 29 September 2023
Accepted after revision: 23 January 2024
Article published online:
06 June 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimerʼs disease. The Lancet 2021; 397: 1577-1590 DOI: 10.1016/S0140-6736(20)32205-4.
- 2 Alzheimerʼs Disease International Dementia Statistics. Accessed September 8, 2023 at: https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
- 3 Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. Cell 2019; 179: 312-339 DOI: 10.1016/j.cell.2019.09.001.
- 4 Jack jr. CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R. Contributors NIA-AA research framework. Toward a biological definition of alzheimerʼs disease. Alzheimers Dement 2018; 14: 535-562 DOI: 10.1016/j.jalz.2018.02.018.
- 5 U.S. Food and Drug Administration. FDA Grants Accelerated Approval for Alzheimerʼs Disease Treatment. Accessed November 29, 2023 at: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment
- 6 U.S. Food and Drug Administration. FDAʼs Decision to Approve New Treatment for Alzheimerʼs Disease. Accessed November 29, 2023 at: https://www.fda.gov/drugs/our-perspective/fdas-decision-approve-new-treatment-alzheimers-disease
- 7 Madnani RS. Alzheimerʼs disease: A mini-review for the clinician. Front Neurol 2023; 14: 1178588 DOI: 10.3389/fneur.2023.1178588.
- 8 The Lancet Lecanemab for Alzheimerʼs Disease. Tempering hype and hope. The Lancet 2022; 400: 1899 DOI: 10.1016/S0140-6736(22)02480-1.
- 9 Miculas DC, Negru PA, Bungau SG, Behl T, ul Hassan SS, Tit DM. Pharmacotherapy evolution in alzheimerʼs disease: Current framework and relevant directions. Cells 2022; 12: 131 DOI: 10.3390/cells12010131.
- 10 Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for alzheimerʼs disease: Beyond cholinesterase inhibitors. Pharmacol Ther 2012; 134: 8-25 DOI: 10.1016/j.pharmthera.2011.12.002.
- 11 Ng YP, Or TCT, Ip NY. Plant alkaloids as drug leads for alzheimerʼs disease. Neurochem Int 2015; 89: 260-270 DOI: 10.1016/j.neuint.2015.07.018.
- 12 Smyrska-Wieleba N, Mroczek T. Natural inhibitors of cholinesterases: Chemistry, structure–activity and methods of their analysis. Int J Mol Sci 2023; 24: 2722 DOI: 10.3390/ijms24032722.
- 13 Jaborosa Juss. Accessed September 11, 2023: https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:38397-1
- 14 Chiarini FE, Barboza GE. Karyological studies in Jaborosa (Solanaceae). Bot J Linn Soc 2008; 156: 467-478 DOI: 10.1111/j.1095-8339.2007.00734.x.
- 15 Flora Argentina. Accessed September 11, 2023: http://www.floraargentina.edu.ar/
- 16 Alza NP, Richmond V, Baier CJ, Freire E, Baggio R, Murray AP. Synthesis and cholinesterase inhibition of cativic acid derivatives. Bioorg Med Chem 2014; 22: 3838-3849 DOI: 10.1016/j.bmc.2014.06.030.
- 17 Cavallaro V, Alza NP, Murray MG, Murray AP. Alkaloids from Habranthus tubispathus and H. jamesonii, two amaryllidaceae with acetyl- and butyrylcholinesterase inhibition activity. Nat Prod Commun 2014; 9: 159-162
- 18 Alza NP, Murray AP. Chemical constituents and acetylcholinesterase inhibition of senecio ventanensis cabrera (Asteraceae). Rec Nat Prod 2016; 10: 513-518
- 19 Cavallaro V, Baier CJ, Murray MG, Estévez-Braun A, Murray AP. Neuroprotective effects of Flaveria Bidentis and Lippia Salsa extracts on SH-SY5Y cells. S Afr J Bot 2018; 119: 318-324 DOI: 10.1016/j.sajb.2018.10.006.
- 20 Cirigliano AM, Misico RI. Spiranoid withanolides from Jaborosa Odonelliana and Jaborosa Runcinata . Z Naturforsch B 2005; 60: 867-869 DOI: 10.1515/znb-2005-0808.
- 21 Cirigliano AM, Veleiro AS, Bonetto GM, Oberti JC, Burton G. Spiranoid withanolides from Jaborosa Runcinata and Jaborosa Araucana . J Nat Prod 1996; 59: 717-721 DOI: 10.1021/np960210i.
- 22 García ME, Nicotra VE, Oberti JC, Ríos-Luci C, León LG, Marler L, Li G, Pezzuto JM, van Breemen RB, Padrón JM, Hueso-Falcón I, Estévez-Braun A. Antiproliferative and quinone reductase-inducing activities of withanolides derivatives. Eur J Med Chem 2014; 82: 68-81 DOI: 10.1016/j.ejmech.2014.05.045.
- 23 Monteagudo ES, Burton G, Gonzalez CM, Oberti JC, Gros EG. 14β,17β- dihydroxywithanolides from Jaborosa Bergii. Phytochemistry 1988; 27: 3925-3928 DOI: 10.1016/0031-9422(88)83046-2.
- 24 Nicotra VE, Gil RR, Vaccarini C, Oberti JC, Burton G. 15, 21-cyclowithanolides from Jaborosa Bergii. J Nat Prod 2003; 66: 1471-1475 DOI: 10.1021/np030248c.
- 25 González U, Nieto-Camacho A, Hernández-Ortega S, Martínez M, Maldonado E. Withanolides from Datura Ceratocaula and Datura Discolor and their acetylcholinesterase inhibitory activity. Fitoterapia 2023; 170: 105655 DOI: 10.1016/j.fitote.2023.105655.
- 26 Choudhary MI, Nawaz SA, ul-Haq Z, Lodhi MA, Ghayur MN, Jalil S, Riaz N, Yousuf S, Malik A, Gilani AH, ur-Rahman A. Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties. Biochem Biophys Res Commun 2005; 334: 276-287 DOI: 10.1016/j.bbrc.2005.06.086.
- 27 Xia G, Cao S, Chen L, Qiu F. Natural withanolides, an update. Nat Prod Rep 2022; 39: 784-813 DOI: 10.1039/D1NP00055A.
- 28 Chen LX, He H, Qiu F. Natural withanolides: An overview. Nat Prod Rep 2011; 28: 705 DOI: 10.1039/c0np00045k.
- 29 Veleiro AS, Oberti JC, Burton G. Chemistry and Bioactivity of Withanolides from South American Solanaceae. In: Atta-ur-Rehman (ed.): Studies in Natural Products Chemistry, Vol. 32. Amsterdam: Elsevier; 2005: 1019-1052
- 30 Lavie D, Bessalle R, Pestchanker MJ, Gottlieb HE, Frolow F, Giordano OS. Trechonolide A, a new withanolide type from Trechonaetes Laciniata . Phytochemistry 1987; 26: 1791-1795 DOI: 10.1016/S0031-9422(00)82290-6.
- 31 Monteagudo ES, Oberti JC, Gros EG, Burton G. A spiranic withanolide from Jaborosa Odonelliana . Phytochemistry 1990; 29: 933-935 DOI: 10.1016/0031-9422(90)80049-M.
- 32 Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95 DOI: 10.1016/0006-2952(61)90145-9.
- 33 Blaženović I, Kind T, Ji J, Fiehn O. Software tools and approaches for compound identification of LC-MS/MS data in metabolomics. Metabolites 2018; 8: 31 DOI: 10.3390/metabo8020031.
- 34 Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TW, Fiehn O, Goodacre R, Griffin JL, Hankemeier T, Hardy N, Harnly J, Higashi R, Kopka J, Lane AN, Lindon JC, Marriott P, Nicholls AW, Reily MD, Thaden JJ, Viant MR. Proposed minimum reporting standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 2007; 3: 211-221 DOI: 10.1007/s11306-007-0082-2.
- 35 Liebisch G, Fahy E, Aoki J, Dennis EA, Durand T, Ejsing CS, Fedorova M, Feussner I, Griffiths WJ, Köfeler H, Merrill Jr AH, Murphy RC, OʼDonnell VB, Oskolkova O, Subramaniam S, Wakelam MJO, Spener F. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J Lipid Res 2020; 61: 1539-1555 DOI: 10.1194/jlr.S120001025.